Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 119
Filter
1.
Br J Cancer ; 109(8): 2072-8, 2013 Oct 15.
Article in English | MEDLINE | ID: mdl-24045661

ABSTRACT

BACKGROUND: We previously reported that expressions of the pro-angiogenic cytokines angiopoietin-2 (Ang-2), follistatin, granulocyte colony-stimulating factor, hepatocyte growth factor, leptin, platelet-derived growth factor-BB, platelet endothelial cell adhesion molecule-1, and vascular endothelial growth factor were associated with the response to sorafenib in patients with advanced hepatocellular carcinoma (HCC). The aim of the present study is to examine the same relationship in a larger cohort. METHODS: In the current retrospective cohort study, we measured serum levels of the eight cytokines in 120 consecutive HCC patients who were treated with sorafenib. We evaluated the effects of increased expression of serum cytokines on progression-free survival (PFS) and overall survival (OS). RESULTS: Elevated expression of Ang-2 correlated both with significantly shorter PFS (hazard ratio (HR), 1.84; 95% confidence interval (CI), 1.21-2.81), and OS (HR, 1.95; 95% CI, 1.21-3.17). Patients with more than three cytokines expressed above the median similarly had significantly shorter PFS (HR, 1.98; 95% CI, 1.30-3.06) and OS (HR, 1.94; 95% CI, 1.19-3.22). Differences in OS were evident in cases with the evidence of macroscopic vascular invasion or extrahepatic metastasis. CONCLUSION: High expression of Ang-2 or more than cytokines in serum is associated with poor PFS and OS in HCC patients treated with sorafenib.


Subject(s)
Carcinoma, Hepatocellular/blood , Cytokines/blood , Liver Neoplasms/blood , Adult , Aged , Aged, 80 and over , Angiopoietin-2/blood , Antineoplastic Agents/therapeutic use , Carcinoma, Hepatocellular/blood supply , Carcinoma, Hepatocellular/drug therapy , Cohort Studies , Female , Humans , Liver Neoplasms/blood supply , Liver Neoplasms/drug therapy , Male , Middle Aged , Neovascularization, Pathologic/blood , Niacinamide/analogs & derivatives , Niacinamide/therapeutic use , Phenylurea Compounds/therapeutic use , Retrospective Studies , Sorafenib
3.
Diabetologia ; 54(7): 1921-9, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21499675

ABSTRACT

AIMS/HYPOTHESIS: Severe hypoglycaemia associated with diabetes management is a potential risk for cardiovascular diseases. However, the effect and mechanism of hypoglycaemia on the progression of atherosclerosis remains largely unknown. As a first step towards elucidating the above, we investigated the effect of hypoglycaemia on monocyte-endothelial interaction. METHODS: Insulin was injected intraperitoneally once every 3 days for 5 weeks in Goto-Kakizaki rats, a non-obese rat model of type 2 diabetes. We counted the number of monocytes adherent to the endothelium of thoracic aorta as an index of early atherosclerogenesis. Cultured HUVEC were used to investigate the mechanism of action. RESULTS: Insulin treatment increased the number of monocytes adherent to the vascular endothelium. This increase was abrogated by injection of glucose with insulin. Amosulalol, an α-1 and ß-adrenoreceptor antagonist, suppressed monocyte adhesion to endothelium and levels of adhesion molecules (intercellular adhesion molecule-1 and vascular cell adhesion molecule-1) in the endothelial surface, which had been enhanced by insulin-induced hypoglycaemia. In HUVEC, adrenaline (epinephrine) significantly increased nuclear translocation of nuclear factor-κB (NF-κB) p65 and levels of adhesion molecules, effects that were abrogated following addition of SQ22536, a specific adenyl cyclase inhibitor. CONCLUSIONS/INTERPRETATION: Our data indicate that repetitive hypoglycaemia induced by insulin enhanced monocyte adhesion to endothelial cells in Goto-Kakizaki rat aorta through enhanced adrenaline activity and that the latter stimulated intracellular cAMP, leading to nuclear translocation of NF-κB with subsequent production of adhesion molecules in endothelial cells.


Subject(s)
Aorta, Thoracic/cytology , Endothelial Cells/cytology , Endothelial Cells/metabolism , Epinephrine/blood , Hypoglycemia/physiopathology , Monocytes/cytology , Animals , Cell Adhesion/physiology , Cells, Cultured , Humans , Male , Rats , Reverse Transcriptase Polymerase Chain Reaction
4.
Aliment Pharmacol Ther ; 33(3): 378-88, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21118396

ABSTRACT

BACKGROUND: Moderate alcohol consumption may have certain beneficial effects against non-alcoholic fatty liver disease, which is associated with metabolic syndrome. AIM: To determine the association between drinking pattern and fatty liver in Japanese men and women. METHODS: A cross-sectional study was performed with health checkup data including information concerning alcohol consumption and ultrasonographic assessment of fatty liver. RESULTS: We analysed 4957 men and 2155 women without reported liver diseases (median age, 49 years). In men, 40% of nondrinkers and 28% of drinkers had fatty liver. Alcohol consumption was inversely associated with fatty liver (adjusted odds ratio, 0.54; 95% confidence interval, 0.46-0.63). The prevalence of fatty liver in each category of drinking frequency was 38% (1-3 days/week), 29% (4-6 days/week), and 24% (daily drinking); there was a significant inverse correlation between drinking frequency and the prevalence of fatty liver (P < 0.001). In women, 16% of nondrinkers and 10% of drinkers had fatty liver. Drinking less than 20 g on 1-3 days/week was associated with low prevalence of fatty liver (adjusted odds ratio, 0.47; 95% confidence interval, 0.23-0.96). CONCLUSIONS: Alcohol consumption appears to protect against non-alcoholic fatty liver disease.


Subject(s)
Alcohol Drinking/epidemiology , Metabolic Syndrome/complications , Adult , Alcohol Drinking/adverse effects , Asian People , Cross-Sectional Studies , Fatty Liver/epidemiology , Fatty Liver/etiology , Fatty Liver/prevention & control , Female , Humans , Japan/epidemiology , Male , Metabolic Syndrome/epidemiology , Middle Aged , Non-alcoholic Fatty Liver Disease , Risk Factors , Statistics as Topic , Time Factors , Ultrasonography
5.
Eur Respir Rev ; 19(117): 248-52, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20956201

ABSTRACT

Large cell carcinoma of the lung with a rhabdoid phenotype is a rare type of lung cancer, and does not commonly metastasize to the small intestine. Herein we describe a 63-yr-old Japanese male with ileus resulting from small intestinal metastasis from lung cancer. Tumour enlargement was rapid and could not be treated with chemotherapy.


Subject(s)
Carcinoma, Large Cell/complications , Carcinoma, Large Cell/secondary , Intussusception/etiology , Intussusception/pathology , Lung Neoplasms/complications , Lung Neoplasms/pathology , Fatal Outcome , Humans , Intestine, Small/pathology , Intestine, Small/surgery , Intussusception/surgery , Male , Middle Aged , Phenotype , Rhabdoid Tumor/complications , Rhabdoid Tumor/secondary
6.
J Antimicrob Chemother ; 65(5): 842-52, 2010 May.
Article in English | MEDLINE | ID: mdl-20233776

ABSTRACT

OBJECTIVES: To determine the mechanism of intermediate- and high-level echinocandin resistance, resulting from heterozygous and homozygous mutations in GSC1 (FKS1), in both laboratory-generated and clinical isolates of Candida albicans. METHODS: The DNA sequences of the entire open reading frames of GSC1, GSL1 (FKS3) and RHO1, which may contribute to the beta-1,3-glucan synthase of a micafungin-susceptible strain and a resistant clinical isolate, were compared. A spontaneous heterozygous mutant isolated by selection for micafungin resistance, and a panel of laboratory-generated homozygous and heterozygous mutants that possessed combinations of the echinocandin-susceptible and -resistant alleles, or mutants with individual GSC1 alleles deleted, were used to compare levels of echinocandin resistance and inhibition of glucan synthase activity. RESULTS: DNA sequence analysis identified a mutation, S645P, in both alleles of GSC1 from the clinical isolate. GSL1 had two homozygous amino acid changes and five non-synonymous nucleotide polymorphisms due to allelic variation. The predicted amino acid sequence of Rho1p was conserved between strains. Reconstruction of the heterozygous (S645/S645F) and homozygous (S645F/S645F) mutation showed that the homozygous mutation conferred a higher level of micafungin resistance (4 mg/L) than the heterozygous mutation (1 mg/L). Exposure of the heterozygous mutant to micafungin resulted in a loss of heterozygosity. Kinetic analysis of beta-1,3-glucan synthase activity showed that the homozygous and heterozygous mutations gave echinocandin susceptibility profiles that correlated with their MIC values. CONCLUSIONS: A homozygous hot-spot mutation in GSC1, caused by mutation in one allele and then loss of heterozygosity, is required for high-level echinocandin resistance in C. albicans. Both alleles of GSC1 contribute equally and independently to beta-1,3-glucan synthase activity.


Subject(s)
Antifungal Agents/pharmacology , Candida albicans/drug effects , Candida albicans/enzymology , Drug Resistance, Fungal , Echinocandins/pharmacology , Fungal Proteins/metabolism , Glucosyltransferases/metabolism , Lipopeptides/pharmacology , Adult , Animals , Catalytic Domain/genetics , DNA, Fungal/chemistry , DNA, Fungal/genetics , Fungal Proteins/genetics , Glucosyltransferases/genetics , Humans , Loss of Heterozygosity , Male , Micafungin , Microbial Sensitivity Tests , Molecular Sequence Data , Mutation, Missense , Protein Processing, Post-Translational , Sequence Analysis, DNA
7.
Aliment Pharmacol Ther ; 31(3): 407-14, 2010 Feb 01.
Article in English | MEDLINE | ID: mdl-19849688

ABSTRACT

BACKGROUND: The surveillance of hepatocellular carcinoma (HCC) has become prevalent, and the modalities for its treatment have improved. AIM: To understand the changes that occur in the characteristics and prognostic factors of HCC with time. METHODS: Newly diagnosed HCC patients were divided into two groups; patients treated before 31 December 2000 (n = 504), and after 1 January 2001 (n = 746), and their clinical backgrounds and prognostic factors were analysed. RESULTS: The number of patients negative for both Hepatitis B surface antigen (HBsAg) and Hepatitis C virus antibody (HCVAb) increased with time (NBNC-HCC). The size of HCC decreased in patients who were positive for HBsAg (B-HCC) or HCVAb (C-HCC), whereas no difference was observed in NBNC-HCC. The patient survival of C-HCC improved; however, no difference was detected for NBNC-HCC. In multivariate analysis, low albumin, high aspartate aminotransferase (AST), ascites, large tumour size, multiple tumour number and high alpha-fetoprotein were risk factors for survival before 2000, whereas the presence of HBsAg was additionally selected as a good prognostic factor and AST was excluded after 2001. CONCLUSIONS: The prognostic factors as well as clinical background of HCC changed with time, and the presence of HBsAg was found to be an additional good prognostic factor after 2001.


Subject(s)
Carcinoma, Hepatocellular/diagnosis , Hepatitis B Surface Antigens , Hepatitis C Antibodies , Liver Neoplasms/diagnosis , Aged , Biomarkers, Tumor/immunology , Carcinoma, Hepatocellular/epidemiology , Carcinoma, Hepatocellular/immunology , DNA, Viral/immunology , Female , Humans , Japan/epidemiology , Liver Neoplasms/epidemiology , Liver Neoplasms/immunology , Male , Middle Aged , Prevalence , Prognosis , Risk Factors
8.
Dig Liver Dis ; 42(1): 51-4, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19473895

ABSTRACT

BACKGROUND: In Caucasians with autoimmune hepatitis, patients with acute presentation have autoimmune thyroiditis and histological zone 3 necrosis more frequently. AIM: We aimed at investigating clinical features of Japanese autoimmune hepatitis patients with acute presentation. METHODS: Of 176 patients retrospectively reviewed, 53 were diagnosed with acute presentation. RESULTS: Patients with acute presentation had higher serum levels of bilirubin and transaminase, lower frequencies of autoimmune thyroiditis and antinuclear antibodies of 1:160 or greater, and a higher frequency of zone 3 necrosis. Of the 53 patients with acute presentation, 10 showed histological acute hepatitis; however, advanced staging of fibrosis was found in 13 patients. In patients with acute presentation, those with histological acute hepatitis were younger than those with chronic hepatitis. The cumulative incidental rate of the normalization of serum alanine aminotransferase levels with prednisolone treatment was similar between patients with acute presentation and those with classical presentation. CONCLUSIONS: In line with previous results, zone 3 necrosis is a histological characteristic of autoimmune hepatitis with acute presentation. Autoimmune hepatitis with acute presentation includes not only histological acute hepatitis but also acute exacerbation of pre-existing chronic disease. On the other hand, Japanese patients with acute presentation may also have different clinical features from Caucasian patients.


Subject(s)
Hepatitis, Autoimmune/blood , Hepatitis, Autoimmune/pathology , Acute Disease , Adolescent , Adult , Age Distribution , Aged , Alanine Transaminase/blood , Antibodies, Antinuclear/blood , Bilirubin/blood , Female , HLA-DR4 Antigen , Hepatitis, Autoimmune/epidemiology , Humans , Japan/epidemiology , Male , Middle Aged , Retrospective Studies , Young Adult
9.
Diabetologia ; 51(10): 1883-92, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18654758

ABSTRACT

AIMS/HYPOTHESIS: Ectopic activation of hedgehog (HH) signalling in pancreas induces various abnormal morphogenetic events in the pancreas. This study analysed the dose-dependent requirement of patched homologue 1 (PTCH1), a negative regulator of HH signalling on pancreatic development. METHODS: We used a recessive spontaneous mutant mouse denoted as mes which carries a mutated Ptch1 resulting in deletion of the most carboxy-terminal cytoplasmic domain of the PTCH1 protein. In this study, we analysed pancreatic morphology in Ptch1 ( +/+ ), Ptch1 ( +/mes ), Ptch1 (+/-), Ptch1 ( mes/me ) (s) and Ptch1 (-/mes ) mouse embryos, as well as the islet mass in adult Ptch1 (+/+), Ptch1 (+/mes ) and Ptch1 (+/-) mice. RESULTS: Until embryonic day (E) 12.5, no obvious abnormality of pancreas was observed in any of the Ptch1 mutants. The levels of PDX1 and glucagon were also not evidently different among the mice genotypes studied. Thereafter, morphological abnormalities appeared in the Ptch1 mutant mice. The beta, alpha and exocrine cell masses decreased at E18.5 in parallel with increased HH signalling, with beta cell mass showing the highest sensitivity to HH signalling with a significant decrease even in Ptch1 (+/mes ) mice. Adult Ptch1 (+/-) mice also showed a significant decrease in beta cell mass compared with wild-type mice. CONCLUSIONS/INTERPRETATION: Our findings indicate that the carboxy-terminal domain of Ptch1 is essential for pancreatic development. In addition, the loss of Ptch1 function decreases both the endocrine and exocrine cell mass in a dose-dependent manner, with beta cells particularly sensitive to changes in HH signalling.


Subject(s)
Cell Differentiation/physiology , Insulin-Secreting Cells/metabolism , Receptors, Cell Surface/physiology , Animals , Cell Differentiation/genetics , Immunohistochemistry , Insulin-Secreting Cells/cytology , Mice , Mice, Knockout , Pancreas/cytology , Pancreas/metabolism , Patched Receptors , Patched-1 Receptor , Receptors, Cell Surface/genetics , Receptors, Cell Surface/metabolism , Reverse Transcriptase Polymerase Chain Reaction
10.
Oncogene ; 27(26): 3739-45, 2008 Jun 12.
Article in English | MEDLINE | ID: mdl-18212736

ABSTRACT

Deregulated nuclear factor kappaB (NF-kappaB) activation plays an important role in inflammation and tumorigenesis. ABIN proteins have been characterized as negative regulators of NF-kappaB signaling. However, their mechanism of NF-kappaB inhibition remained unclear. With the help of a yeast two-hybrid screen, we identified ABIN proteins as novel ubiquitin-interacting proteins. The minimal ubiquitin-binding domain (UBD) corresponds to the ABIN homology domain 2 (AHD2) and is highly conserved in ABIN-1, ABIN-2 and ABIN-3. Moreover, this region is also present in NF-kappaB essential modulator/IkappaB kinase gamma (NEMO/IKKgamma) and the NEMO-like protein optineurin, and is therefore termed UBD in ABIN proteins and NEMO (UBAN). Nuclear magnetic resonance studies of the UBAN domain identify it as a novel type of UBD, with the binding surface on ubiquitin being significantly different from the binding surface of other UBDs. ABIN-1 specifically binds ubiquitinated NEMO via a bipartite interaction involving its UBAN and NEMO-binding domain. Mutations in the UBAN domain led to a loss of ubiquitin binding and impaired the NF-kappaB inhibitory potential of ABINs. Taken together, these data illustrate an important role for ubiquitin binding in the negative regulation of NF-kappaB signaling by ABINs and identify UBAN as a novel UBD.


Subject(s)
DNA-Binding Proteins/physiology , NF-kappa B/antagonists & inhibitors , Ubiquitin/metabolism , Binding Sites , Cell Line , DNA-Binding Proteins/chemistry , Humans , NF-kappa B/physiology , Protein Structure, Tertiary , Signal Transduction , Two-Hybrid System Techniques
11.
Biochem Soc Trans ; 35(Pt 5): 942-5, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17956251

ABSTRACT

The NF-kappaB (nuclear factor kappaB) transcription factors control cell survival, proliferation and innate and adaptive immune response. Post-translational modifications of key components of the NF-kappaB pathway provide the molecular basis for signal transmission from the cell membrane to the nucleus. Here, we describe the involvement of different types of ubiquitin modification in the regulation of the NF-kappaB signalling pathway.


Subject(s)
NF-kappa B/metabolism , Signal Transduction , Ubiquitin/metabolism , Cell Membrane/metabolism , Cell Nucleus/metabolism
12.
Diabetologia ; 50(1): 131-41, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17093946

ABSTRACT

AIMS/HYPOTHESIS: Recent studies have identified the involvement of inhibitor IkappaB kinase (IKK) in the pathogenesis of insulin resistance. To investigate the mechanism involved, we examined the role of nuclear factor kappaB (NF-kappaB), the distal target of IKK, in hepatic glucose metabolism. METHODS: To inhibit NF-kappaB activity, db/db mice were infected with adenovirus expressing the IkappaBalpha super-repressor. RESULTS: The IkappaBalpha super-repressor adenovirus infection caused a moderate reduction of NF-kappaB activity in liver. The treatment was associated with improved glucose tolerance, reduction in the serum insulin level, and increased hepatic triacylglycerol and glycogen contents, but had no effect on insulin-stimulated phosphorylation of Akt. On the other hand, quantification of mRNA in the liver revealed marked reduction of expression of gluconeogenic genes, such as those encoding phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase, concurrent with reduced expression of gene encoding peroxisome proliferator-activated receptor gamma coactivator-1alpha (PPARGC1A, also known as PGC-1alpha). Furthermore, the production of super-repressor IkappaBalpha suppressed the increase in blood glucose level after pyruvate injection. CONCLUSIONS/INTERPRETATION: Our results indicate that moderate inhibition of NF-kappaB improved glucose tolerance through decreased gluconeogenesis associated with reduced PGC-1alpha gene expression in db/db mice, and suggest that inhibition of NF-kappaB activity in liver is a potentially suitable strategy for the normalisation of blood glucose concentration in type 2 diabetes.


Subject(s)
Diabetes Mellitus/metabolism , Glucose/metabolism , Liver/metabolism , NF-kappa B/antagonists & inhibitors , AMP-Activated Protein Kinases , Adenoviridae/genetics , Animals , Cyclic AMP Response Element-Binding Protein/metabolism , Diabetes Mellitus/physiopathology , Disease Models, Animal , Female , Glycogen/metabolism , I-kappa B Proteins/genetics , I-kappa B Proteins/metabolism , Insulin Resistance/physiology , Mice , Mice, Inbred C57BL , Multienzyme Complexes/metabolism , NF-kappa B/metabolism , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha , Protein Serine-Threonine Kinases/metabolism , STAT3 Transcription Factor/metabolism , Trans-Activators/physiology , Transcription Factors , Triglycerides/metabolism
13.
Antimicrob Agents Chemother ; 50(4): 1148-55, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16569823

ABSTRACT

The micafungin and caspofungin susceptibilities of Candida albicans laboratory and clinical isolates and of Saccharomyces cerevisiae strains stably hyperexpressing fungal ATP-binding cassette (ABC) or major facilitator superfamily (MFS) transporters involved in azole resistance were determined using three separate methods. Yeast strains hyperexpressing individual alleles of ABC transporters or an MFS transporter from C. albicans gave the expected resistance profiles for the azoles fluconazole, itraconazole, and voriconazole. The strains hyperexpressing CDR2 showed slightly decreased susceptibility to caspofungin in agar plate drug resistance assays, as previously reported, but increased susceptibility to micafungin compared with either the strains hyperexpressing CDR1 or the null parent deleted of seven ABC transporters. The strains hyperexpressing CDR1 showed slightly decreased susceptibility to micafungin in these assays. A C. albicans clinical isolate overexpressing both Cdr1p and Cdr2p relative to its azole-sensitive isogenic progenitor acquired resistance to azole drugs and showed reduced susceptibility to caspofungin and slightly increased susceptibility to micafungin in agar plate drug resistance assays. None of the strains showed significant resistance to micafungin or caspofungin in liquid microdilution susceptibility assays. The antifungal activities of micafungin and caspofungin were similar in agarose diffusion assays, although the shape and size of the caspofungin inhibitory zones were affected by medium composition. The assessment of micafungin and caspofungin potency is therefore assay dependent; the differences seen with agar plate drug resistance assays occur over narrow ranges of echinocandin concentrations and are not of clinical significance.


Subject(s)
ATP-Binding Cassette Transporters/genetics , Antifungal Agents/pharmacology , Candida albicans/drug effects , Fungal Proteins/genetics , Lipoproteins/pharmacology , Membrane Transport Proteins/genetics , Peptides, Cyclic/pharmacology , Candida albicans/genetics , Caspofungin , Diffusion , Drug Resistance, Fungal , Echinocandins , Genes, MDR , Lipopeptides , Micafungin , Microbial Sensitivity Tests
14.
Braz J Med Biol Res ; 36(4): 485-9, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12700826

ABSTRACT

Visceral leishmaniasis in Brazil is caused by Leishmania (Leishmania) chagasi and the dog is its most important reservoir. The clinical features in dogs include loss of weight, lymphadenopathy, renal failure, skin lesions, fever, hypergammaglobulinemia, hepatosplenomegaly, anemia, and, rarely, neurological symptoms. Most infected animals develop active disease, characterized by high anti-leishmania antibody titers and depressed lymphoproliferative ability. Antibody production is not primarily important for protection but might be involved in the pathogenesis of tissue lesions. An ELISA test was used to determine if there is an association between neurological symptoms and the presence of anti-L. chagasi antibodies in cerebrospinal fluid (CSF). Thirty serum and CSF samples from symptomatic mixed breed dogs (three with neurological symptoms) from a region of high incidence of visceral leishmaniasis in Brazil were examined for antibody using total parasite antigen and anti-dog IgG peroxidase conjugate. A high level of L. chagasi antibodies was observed in sera (mean absorbance SD, 1.939 0.405; negative control, N = 20, 0.154 0.074) and CSF (1.571 0.532; negative control, N = 10, 0.0195 0.040) from all animals studied. This observation suggests that L. chagasi can cause breakdown of filtration barriers and the transfer of antibodies and antigens from the blood to the CSF compartment. No correlation was observed between antibody titer in CSF and neurological symptoms.


Subject(s)
Antibodies, Protozoan/cerebrospinal fluid , Dog Diseases/cerebrospinal fluid , Leishmania donovani/immunology , Leishmaniasis, Visceral/veterinary , Animals , Antibodies, Protozoan/blood , Dog Diseases/blood , Dogs , Enzyme-Linked Immunosorbent Assay/veterinary , Leishmaniasis, Visceral/blood , Leishmaniasis, Visceral/cerebrospinal fluid
15.
Braz. j. med. biol. res ; 36(4): 485-489, Apr. 2003. graf
Article in English | LILACS | ID: lil-331228

ABSTRACT

Visceral leishmaniasis in Brazil is caused by Leishmania (Leishmania) chagasi and the dog is its most important reservoir. The clinical features in dogs include loss of weight, lymphadenopathy, renal failure, skin lesions, fever, hypergammaglobulinemia, hepatosplenomegaly, anemia, and, rarely, neurological symptoms. Most infected animals develop active disease, characterized by high anti-leishmania antibody titers and depressed lymphoproliferative ability. Antibody production is not primarily important for protection but might be involved in the pathogenesis of tissue lesions. An ELISA test was used to determine if there is an association between neurological symptoms and the presence of anti-L. chagasi antibodies in cerebrospinal fluid (CSF). Thirty serum and CSF samples from symptomatic mixed breed dogs (three with neurological symptoms) from a region of high incidence of visceral leishmaniasis in Brazil were examined for antibody using total parasite antigen and anti-dog IgG peroxidase conjugate. A high level of L. chagasi antibodies was observed in sera (mean absorbance ± SD, 1.939 ± 0.405; negative control, N = 20, 0.154 ± 0.074) and CSF (1.571 ± 0.532; negative control, N = 10, 0.0195 ± 0.040) from all animals studied. This observation suggests that L. chagasi can cause breakdown of filtration barriers and the transfer of antibodies and antigens from the blood to the CSF compartment. No correlation was observed between antibody titer in CSF and neurological symptoms


Subject(s)
Animals , Dogs , Antibodies, Protozoan , Dog Diseases , Leishmania donovani , Leishmaniasis, Visceral , Antibodies, Protozoan , Dog Diseases , Enzyme-Linked Immunosorbent Assay , Leishmaniasis, Visceral
16.
Bone ; 31(2): 303-12, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12151083

ABSTRACT

Core-binding factor alpha(1) (Cbfa1) is an essential transcription factor for osteoblastic differentiation and osteogenesis. Bone morphogenetic protein (BMP) is also a powerful inducer of differentiation of pluripotent mesenchymal cells to osteoblast lineage and bone formation. Recent studies suggest that Cbfa1 plays a critical role during BMP-induced osteoblastic differentiation through association with cytoplasmic BMP signaling molecules, Smads. However, other studies have suggested that Cbfa1 may exhibit its osteogenic function without interaction with Smads. Therefore, it remains unclear whether association with Smad is essential for Cbfa1 function. In this study we examine the effects of Cbfa1 on osteoblastic differentiation in the presence or absence of interactions with Smad1 or Smad5 using C2C12 undifferentiated mesenchymal cells. Cbfa1 expression was induced upon stimulation with BMP-2 in C2C12 cells. Introduction of Cbfa1 into C2C12 cells induced osteoblastic differentiation and promoted transactivation of osteocalcin gene promoter without forming the complex with Smad1 or Smad5. Furthermore, in C2C12 cells in which the association of Cbfa1 with Smad1/Smad5 was prevented by the overexpression of the natural antagonist, Smad6, Cbfa1 still induced osteoblastic differentiation and transactivated osteocalcin gene promoter, regardless of BMP-2 stimulation. These results suggest that the interactions with Smad1 or Smad5 are not essential for Cbfa1 to demonstrate its osteogenic actions. However, interactions with Smad1/Smad5 enhance these osteogenic actions of Cbfa1. Of note, BMP-2-induced or Smad-induced osteoblastic differentiation was inhibited by dominant-negative Cbfa1, suggesting that the function of Cbfa1 is critical for BMP-2-induced osteoblastic differentiation. Our results suggest that Cbfa1 is essential and also sufficient to induce osteoblastic differentiation in undifferentiated mesenchymal cells, and establishment of an association with Smad1/Smad5 enhances the osteogenic actions of Cbfa1. On the other hand, Cbfa1 expression requires the activation of Smad1/Smad5 by BMP-2.


Subject(s)
Cell Differentiation/physiology , DNA-Binding Proteins/metabolism , Growth Substances/physiology , Neoplasm Proteins , Osteoblasts/cytology , Osteoblasts/metabolism , Phosphoproteins/metabolism , Trans-Activators/metabolism , Transcription Factors/physiology , Transforming Growth Factor beta , Animals , Bone Morphogenetic Protein 2 , Bone Morphogenetic Proteins/pharmacology , Cell Differentiation/drug effects , Cell Line , Cells, Cultured , Core Binding Factor Alpha 1 Subunit , Core Binding Factors , Growth Substances/biosynthesis , Growth Substances/metabolism , Mice , Smad Proteins , Smad1 Protein , Smad5 Protein , Transcription Factors/biosynthesis , Transcription Factors/metabolism
17.
Chemotherapy ; 48(2): 78-81, 2002 May.
Article in English | MEDLINE | ID: mdl-12011539

ABSTRACT

The in vitro antifungal activity of FK463 against a variety of clinically important opportunistic molds was compared with amphotericin B, itraconazole and fluconazole by using the broth microdilution method M27-A specified by the National Committee for Clinical Laboratory Standards. FK463 exhibited potent activity against Aspergillus species, which was superior to those of all other compounds tested. FK463 was also active against the dematiaceous fungi Cladosporium trichoides, Exophiala spinifera, Fonsecaea pedrosoi, and Exophiala dermatitidis except for certain clinical isolates. However, FK463 had no activity against Fusarium solani, Pseudallesheria boydii, and the zygomycetes Absidia corymbifera, Cunninghamella elegans, Rhizopus oryzae, and Rhizopus microsporus var. rhizopodiformis. These results suggest that FK463 has potential utility for the treatment for infections caused by Aspergillus species and dematiaceous fungi.


Subject(s)
Aspergillus/drug effects , Lipoproteins/pharmacology , Peptides, Cyclic/pharmacology , Aspergillus/pathogenicity , Echinocandins , Fungi/drug effects , Fungi/pathogenicity , Lipopeptides , Micafungin , Microbial Sensitivity Tests
18.
Rev Hosp Clin Fac Med Sao Paulo ; 56(4): 115-8, 2001.
Article in English | MEDLINE | ID: mdl-11717718

ABSTRACT

Microlaparoscopy represents the development of endoscopic surgery towards a minimally invasive surgical procedure. The advantages include fewer surgical complications, faster return to daily activities, more comfortable postoperative recovery, and satisfactory aesthetic results. The possibility of performing surgery under sedation may result in shorter hospitalization, lower hospital costs, and easier anesthetic procedures. The authors report their preliminary experience with the use of microlaparoscopy, using optics and 2mm instruments, as well as a review of the literature since the introduction of this new technique. The report of these 16 cases demonstrates that microlaparoscopy is a feasible technique with satisfactory results. On the other hand, this new technique requires precise indications and a training period for the development of the skills necessary for performing these surgeries.


Subject(s)
Endometriosis/surgery , Laparoscopy/methods , Adolescent , Adult , Female , Humans , Length of Stay
19.
Anticancer Res ; 21(4B): 2963-7, 2001.
Article in English | MEDLINE | ID: mdl-11712794

ABSTRACT

The purpose of this study was to compare the results of 133 cases (131 patients) of subcutaneous mastectomy with axillary dissection between 1983 and 1999 and 910 cases of radical mastectomy during the same period. The median follow-up period of the subcutaneous mastectomy group and the radical mastectomy group were 66 months and 81 months, respectively. The age at operation was significantly (p<0.01) younger in the subcutaneous mastectomy group than in the radical mastectomy group and the clinical stage was significantly (p<0.01) earlier. Lymph node metastasis was significantly (p<0.01) higher in the radical mastectomy than in the subcutaneous mastectomy group. There was no difference in ER status between the two groups. There was local recurrence in 5 (3.8%) members of the subcutaneous mastectomy group and in 12 (1.3%) members of the radical mastectomy group. There was no difference in disease-free survival and overall survival between the two groups. Divided into two subgroups by lymph node status, there was no difference in disease-free survival and overall survival between the two groups. Local recurrence occurred more frequently (p<0.05) in the subcutaneous mastectomy group, however, than in the radical mastectomy group when no lymph node metastasis was found. Multivariate analysis using the Cox hazard model showed that operation method and lymph node status were independent prognostic factors for local recurrence, whereas, lymph node status and ER status were independent prognostic factors of disease-free survival. In conclusion, subcutaneous mastectomy presents a risk factor for local recurrence, but the survival rate of the subcutaneous mastectomy group is as favourable as the radical mastectomy group.


Subject(s)
Breast Neoplasms/surgery , Mastectomy, Radical , Mastectomy, Subcutaneous , Adult , Age Factors , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Axilla , Breast Neoplasms/chemistry , Breast Neoplasms/drug therapy , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Chemotherapy, Adjuvant , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Disease-Free Survival , Drug Combinations , Female , Fluorouracil/administration & dosage , Humans , Japan/epidemiology , Life Tables , Lymph Node Excision , Lymphatic Metastasis , Middle Aged , Mitomycin/administration & dosage , Neoplasm Proteins/analysis , Neoplasm Recurrence, Local , Prednisolone/administration & dosage , Proportional Hazards Models , Receptors, Estrogen/analysis , Retrospective Studies , Risk Factors , Survival Analysis , Tamoxifen/administration & dosage , Tegafur/administration & dosage , Treatment Outcome , Uracil/administration & dosage
20.
Antimicrob Agents Chemother ; 45(9): 2450-4, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11502513

ABSTRACT

beta-Lactams have been considered ineffective against organisms growing inside mammalian cells because of their poor penetration into cells. However, cefixime has been shown to be clinically effective against typhoid fever. The probable mechanism of therapeutic effectiveness of cefixime against typhoid fever was investigated using Salmonella enterica serovar Typhimurium instead of S. enterica serovar Typhi both in a cellular and in a mouse infection model. Cefixime was able to inhibit the growth of serovar Typhimurium inhabiting monocyte-derived THP-1 cells. Elongation of serovar Typhimurium in THP-1 cells was observed microscopically. Apparent morphological changes of serovar Typhimurium in THP-1 cells were also observed by electron microscopy. The concentration of cefixime inside THP-1 cells was almost half (46 to 48%) of the concentration outside the cells when serovar Typhimurium coexisted in the solution. The length of time after oral dosing (8 mg/kg) that cefixime was present-calculated from levels in serum-at a concentration above the MIC at which 90% of the serovar Typhi organisms inside human cells were inhibited was presumed to be more than 12 h. Cefixime also showed excellent activity in the mouse systemic and oral infection models based on infections caused by serovar Typhimurium. It is concluded that a fair amount of cefixime can enter mammalian cells and inhibit the growth of bacteria inside cells when the bacteria are sensitive enough to cefixime, as are serovars Typhimurium and Typhi.


Subject(s)
Cefixime/therapeutic use , Cephalosporins/therapeutic use , Salmonella Infections/drug therapy , Typhoid Fever/drug therapy , Animals , Cell Survival , Disease Models, Animal , Humans , Male , Mice , Mice, Inbred ICR , Microbial Sensitivity Tests , Salmonella/drug effects , Serotyping , Treatment Outcome , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/microbiology , Tumor Cells, Cultured/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...